References
- Llovet JM, Hilgard P, de Oliveira AC, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008; 13: 378-90. doi: 10.1056/NEJMoa0708857
- Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34. doi: 10.1016/S1470-2045(08)70285-7
- Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv238-55. doi: 10.1093/annonc/mdy308
- Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65: 1140-7. doi: 10.1016/j. jhep.2016.07.020
- Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, et al. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study: Sorafenib as a first-line therapy. J Gastroenterol Hepatol 2014; 29: 1463-9. doi: 10.1111/jgh.12542
- Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, et al. Sorafenib in the treatment of hepatocellular carcinoma: a multicentre real-world study. Scand J Gastroenterol 2016; 51: 979-85. doi: 10.3109/00365521.2016.1166518
- Llovet LM, Bruix J. Management of HCC. Hepathology 2008; 48: 1312-27. doi: 10.1002/hep.22506.
- Forner A, Llovet LM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55. doi: 10.1016/S0140-6736(11)61347-0